Translational Research Working Group developmental pathway for immune response modifiers

Martin A. Cheever, Jeffrey Schlom, Louis M. Weiner, H. Kim Lyerly, Mary L. Disis, Addison Greenwood, Oren Grad, William G Nelson

Research output: Contribution to journalArticle

Abstract

TheTranslational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the investment of National Cancer Institute in translational research and envision its future. TheTranslational Research Working Group conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of immune response modifiers such as vaccines and cytokines. A hallmark of the Immune Response Modifier Developmental Pathway is the coordinated development of multiple components. The Immune Response Modifier Pathway was conceived not as a comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway.

Original languageEnglish (US)
Pages (from-to)5692-5699
Number of pages8
JournalClinical Cancer Research
Volume14
Issue number18
DOIs
StatePublished - Sep 15 2008

Fingerprint

Translational Medical Research
National Cancer Institute (U.S.)
Research
Vaccines
Cytokines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Translational Research Working Group developmental pathway for immune response modifiers. / Cheever, Martin A.; Schlom, Jeffrey; Weiner, Louis M.; Lyerly, H. Kim; Disis, Mary L.; Greenwood, Addison; Grad, Oren; Nelson, William G.

In: Clinical Cancer Research, Vol. 14, No. 18, 15.09.2008, p. 5692-5699.

Research output: Contribution to journalArticle

Cheever, MA, Schlom, J, Weiner, LM, Lyerly, HK, Disis, ML, Greenwood, A, Grad, O & Nelson, WG 2008, 'Translational Research Working Group developmental pathway for immune response modifiers', Clinical Cancer Research, vol. 14, no. 18, pp. 5692-5699. https://doi.org/10.1158/1078-0432.CCR-08-1266
Cheever MA, Schlom J, Weiner LM, Lyerly HK, Disis ML, Greenwood A et al. Translational Research Working Group developmental pathway for immune response modifiers. Clinical Cancer Research. 2008 Sep 15;14(18):5692-5699. https://doi.org/10.1158/1078-0432.CCR-08-1266
Cheever, Martin A. ; Schlom, Jeffrey ; Weiner, Louis M. ; Lyerly, H. Kim ; Disis, Mary L. ; Greenwood, Addison ; Grad, Oren ; Nelson, William G. / Translational Research Working Group developmental pathway for immune response modifiers. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 18. pp. 5692-5699.
@article{8c35da548ace423d9b5abe31a0f91516,
title = "Translational Research Working Group developmental pathway for immune response modifiers",
abstract = "TheTranslational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the investment of National Cancer Institute in translational research and envision its future. TheTranslational Research Working Group conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of immune response modifiers such as vaccines and cytokines. A hallmark of the Immune Response Modifier Developmental Pathway is the coordinated development of multiple components. The Immune Response Modifier Pathway was conceived not as a comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway.",
author = "Cheever, {Martin A.} and Jeffrey Schlom and Weiner, {Louis M.} and Lyerly, {H. Kim} and Disis, {Mary L.} and Addison Greenwood and Oren Grad and Nelson, {William G}",
year = "2008",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-08-1266",
language = "English (US)",
volume = "14",
pages = "5692--5699",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Translational Research Working Group developmental pathway for immune response modifiers

AU - Cheever, Martin A.

AU - Schlom, Jeffrey

AU - Weiner, Louis M.

AU - Lyerly, H. Kim

AU - Disis, Mary L.

AU - Greenwood, Addison

AU - Grad, Oren

AU - Nelson, William G

PY - 2008/9/15

Y1 - 2008/9/15

N2 - TheTranslational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the investment of National Cancer Institute in translational research and envision its future. TheTranslational Research Working Group conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of immune response modifiers such as vaccines and cytokines. A hallmark of the Immune Response Modifier Developmental Pathway is the coordinated development of multiple components. The Immune Response Modifier Pathway was conceived not as a comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway.

AB - TheTranslational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the investment of National Cancer Institute in translational research and envision its future. TheTranslational Research Working Group conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of immune response modifiers such as vaccines and cytokines. A hallmark of the Immune Response Modifier Developmental Pathway is the coordinated development of multiple components. The Immune Response Modifier Pathway was conceived not as a comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway.

UR - http://www.scopus.com/inward/record.url?scp=53249086543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53249086543&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-1266

DO - 10.1158/1078-0432.CCR-08-1266

M3 - Article

C2 - 18794077

AN - SCOPUS:53249086543

VL - 14

SP - 5692

EP - 5699

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -